Metformin and low blood pressure
Pro Research Analysisby 
Searched over 400M research papers
Metformin and Low Blood Pressure: A Comprehensive Review
Introduction to Metformin and Blood Pressure
Metformin, a widely used medication for type 2 diabetes mellitus (T2DM), has been studied for its potential effects on blood pressure (BP). This article synthesizes findings from various studies to understand how metformin influences both systolic blood pressure (SBP) and diastolic blood pressure (DBP) in different populations.
Metformin's Effect on Systolic Blood Pressure (SBP)
Meta-Analysis in Nondiabetic Patients
A meta-analysis of randomized controlled trials involving 4113 nondiabetic participants revealed that metformin significantly reduces SBP by an average of 1.98 mmHg. This effect was more pronounced in individuals with impaired glucose tolerance or obesity, showing reductions of 5.03 mmHg and 3.00 mmHg, respectively .
Animal Studies on Salt-Induced Hypertension
In animal models, specifically spontaneously hypertensive rats, metformin was shown to blunt the rise in SBP caused by a high-salt diet. Rats treated with metformin had significantly lower SBP compared to those on a high-salt diet without metformin treatment .
Hypertensive Patients Without Diabetes
A clinical trial involving hypertensive patients without diabetes found no significant reduction in BP when measured by ambulatory blood pressure monitoring (ABPM) after 8 weeks of metformin treatment. However, a notable reduction in waist circumference was observed, suggesting potential indirect cardiovascular benefits .
Metformin's Effect on Diastolic Blood Pressure (DBP)
Meta-Analysis Findings
The same meta-analysis mentioned earlier found no significant effect of metformin on DBP in nondiabetic patients, with a mean difference of -0.67 mmHg .
Postprandial Blood Pressure in T2DM
In patients with T2DM, metformin was found to attenuate the postprandial fall in SBP but did not significantly affect DBP. This suggests that metformin may help stabilize BP fluctuations after meals in diabetic patients .
Mechanisms of Blood Pressure Regulation
Sympathetic Neural Outflow
Short-term administration of metformin has been shown to lower BP by reducing sympathetic neural outflow, which may contribute to its BP-lowering effects in both humans and animal models .
Renal Epithelial Sodium Channel (ENaC)
In diabetic nephropathy models, metformin normalized SBP by reducing the expression and activity of the renal epithelial sodium channel (ENaC), thereby decreasing sodium retention and controlling hypertension .
Adverse Effects and Considerations
Orthostatic Blood Pressure Recovery
A study from the Copenhagen Insulin and Metformin Therapy (CIMT) trial indicated that metformin might adversely affect orthostatic blood pressure recovery in T2DM patients, leading to an increased early drop in orthostatic BP .
Cardio-Renal Damage
In a double transgenic rat model, metformin lowered BP but did not ameliorate hypertensive cardio-renal damage, highlighting the complexity of its effects on cardiovascular health .
Conclusion
Metformin has a modest but significant effect on lowering SBP, particularly in nondiabetic individuals with impaired glucose tolerance or obesity. Its impact on DBP is less clear, with some studies showing no significant changes. The mechanisms behind these effects include reduced sympathetic neural outflow and decreased sodium retention via the renal ENaC. However, potential adverse effects on orthostatic BP recovery and limited impact on hypertensive organ damage warrant further investigation. Overall, metformin's role in BP regulation adds to its profile as a multifaceted therapeutic agent in managing cardiovascular risk factors.
Sources and full results
Most relevant research papers on this topic